Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Breast Neoplasms 17Neoplasms 14Neoplasm Metastasis 10Ovarian Neoplasms 9Melanoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Small Cell Lung Carcinoma 6Recurrence 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Thyroid Neoplasms 5Thyroid Cancer, Papillary 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Colonic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma 4Leukemia, Myeloid, Acute 4Urothelial Cancer 3Stomach Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × Advanced Non-small Cell Lung Cancer × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡